Therefore, the haptoglobin plasma concentration with the associated AKI-protective clinical cutoff values might not only be studied as a future additional marker for disease severity and risk for AKI in patients with ARDS but also as a potential target for treatment with exogenous haptoglobin in future prospective clinical trials. The gene discussed is HP; the disease is acute respiratory distress syndrome.